Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists

By Thibonnier M.  

Expert Opinion on Investigational Drugs, Vol. 7, Iss. 5, 1998-05 ,pp. : 729-740

Informa Healthcare

Access to resources Recommend Favorite

Development and therapeutic indications of orally-active non-peptide vasopressin receptor antagonists

By Paranjape S.B.   Thibonnier M.  

Expert Opinion on Investigational Drugs, Vol. 10, Iss. 5, 2001-05 ,pp. : 825-834

Informa Healthcare

Access to resources Recommend Favorite

The Association between Circulating Secreted Protein Acidic and Rich in Cysteine (SPARC) and Glycosylated Haemoglobin (HbA_1c) during Lifestyle-modified Weight Reduction Intervention in Obese Male Subjects

By Kotani K   Yamada T   Taniguchi N  

The Journal of International Medical Research, Vol. 39, Iss. 2, 2011-03 ,pp. : 528-532

Field House Publishing

Access to resources Recommend Favorite

Effects of the orally active non-peptide bradykinin B 2 receptor antagonist, FR173657, on plasma extravasation in guinea pig airways

By Watanabe M.   Yoshihara S.   Abe T.   Oyama M.   Arisaka O.  

European Journal of Pharmacology, Vol. 367, Iss. 2, 1999-02 ,pp. : 373-378

Elsevier

Access to resources Recommend Favorite

The Management of Hypertension in the Overweight and Obese Patient: Is Weight Reduction Sufficient?

By Jacob S.  

Drugs, Vol. 64, Iss. 11, 2004-01 ,pp. : 1263-1263

Adis International

Access to resources Recommend Favorite